{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-050057","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.190115+00:00","generated_at":"2026-05-29T00:44:20.308088+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"FDA approves Ionis' Tryngolza (olezarsen) as first treatment for familial chylomicronemia syndrome","bullets":["Phase 3 Balance trial: placebo-adjusted mean triglyceride reduction 42.5% at 6 months (p=0.0084), 57% at 12 months.","Acute pancreatitis events: 1 patient (5%) on Tryngolza vs 7 patients (30%) on placebo over 12 months.","Most common adverse reactions: injection site reactions (19% vs 9%), decreased platelets (12% vs 4%), arthralgia (9% vs 0%).","U.S. launch expected before year-end; first of four independent launches planned over next three years.","FCS affects up to ~3,000 people in U.S.; Tryngolza is self-administered monthly via auto-injector."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-050057","json":"https://secwatch.observer/filing/0001140361-24-050057.json","markdown":"https://secwatch.observer/filing/0001140361-24-050057.md","text":"https://secwatch.observer/filing/0001140361-24-050057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036124050057/0001140361-24-050057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036124050057/ef20040455_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:44:20.308088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}